Scalper1 News
Big pharma Bristol-Myers Squibb (BMY) beat Q4 estimates and tried to clarify the progress of its oncology program Friday, sending shares vacillating wildly on the stock market today. On Thursday, Bristol-Myers stock dropped after it posted a new nivolumab trial in lung cancer that sparked worries that this meant the ongoing trial of nivolumab in combination with Yervoy wasn’t going so well. As the market opened Friday the stock rose more than 2%, Scalper1 News
Scalper1 News